Privacy Policy

Privacy statement

Thank you for visiting the Helix BioPharma Corp. website (the “Site”). Below is our privacy policy governing our use of information gathered about you (“Information”). Although we are committed to maintaining your confidence and trust in all of our activities with you, this Privacy Policy does not govern our collection of data through channels other than this Site. If you have any questions about this privacy statement or the content and practices of our web site, please feel free to contact us directly at:

401 Bay Street, Suite 2704 PO Box 4 Toronto ON M5H 2Y4

helix@helixbiopharma.com

Information we collect

We collect Information when you register to access and use certain portions of the Site. We also collect Information from you that is necessary to identify you and to process and fulfill your requests for information or service.

We also may set and access “cookies” on your computer. A cookie is a small piece of data, which often includes an anonymous unique identifier, that is set to your browser from a web site’s computers and is stored on your computer’s hard drive. We use these cookies to keep track of your movements on the Site so we can customize content for your review. Although you may configure your Internet web browser not to accept cookies, you will not be able to access all features of the Site if you disable our ability to use cookies on your browser. BY PROVIDING PERSONAL INFORMATION TO US, YOU SIGNIFY YOUR CONSENT TO OUR COLLECTION, USE AND DISCLOSURE OF YOUR PERSONAL INFORMATION IN ACCORDANCE WITH THIS PRIVACY POLICY. OUR USE OF YOUR PERSONAL INFORMATION

We use information collected from users in order to:

(i) make the Site more useful;

(ii) to respond to your queries;

(iii) to inform users of our new promotions or about our company, products and services offered by us; and

(iv) to provide notifications regarding the Site and our products and services.

Information collected for employment purposes, including resumes submitted online, may be collected, used or disclosed for the purpose of establishing, managing or terminating an employment relationship, or for any other purpose authorized by law.

We restrict access to your Information to those in our organization who require access in order to provide the Site, information and services to you. We may share your Information with the following entities:

Our affiliated companies;

Unaffiliated service providers with whom we subcontract, including web site hosting companies, fulfillment companies, payment processing companies, and other third party service providers; and

Government agencies and law enforcement officials, when required to do so to respond to subpoenas, court orders or legal process, or to establish or exercise or legal rights or to defend against legal claims.

We reserve the right to share Information with other organizations in the following situations:

As permitted by law in order to investigate, prevent, or take action regarding illegal activities, suspected fraud, violation of our intellectual property rights, situations involving potential threats to the physical safety of any person, violations of the Site’s Terms of Use or other agreements, or otherwise as required by law; and

When we need to share Information to provide any product or service you have requested.

We may use your IP address and information about the web pages you visit to gather broad demographic information, interests and behavior so that we may better understand our Site users. This Information may be used, for example, to analyze and improve our Site design and functionality. We may share aggregated demographic, product usage, or traffic pattern information for marketing purposes with other organizations, but these statistics will not include information that identify you personally.

Business transfer

As we continue to develop, we might sell or buy the assets of similar companies. In such transactions, customer and user Information generally is one of the transferred business assets. Also, in the event that we or substantially all of our assets are acquired, such Information may be one of those transferred assets, and we reserve the right to buy or sell such assets.

Opt-out policy

When you provide Information via our web site, we may use the Information to occasionally notify you about special promotional programs and other valuable services we offer. If you prefer that we not contact you in this manner, we will promptly remove you from our mailing list at your request. Please send any such request to the address listed below.

How to review and update your information

To change your information or to withdraw your consent to our collection, use and disclosure of your personal information at any time, within the bounds of legal and/or contractual restrictions and reasonable notice you may write, e-mail or telephone us at the following address: helix@helixbiopharma.com

Security

We use a variety of standard protections to maintain the security of your online session. Although the Site has security measures in place to protect against the loss, misuse and alteration of Information under our control, we cannot guarantee that such security measures will be sufficient, will not be breached, and that your Information may not be disclosed or otherwise accessed in any unauthorized manner. Certain Information may be transmitted to you by electronic mail. Although it may be illegal to intercept or disclose these messages, these transmissions are not secured.

Children's privacy protection

The Site does not target children or provide products or services for use by children. We do not knowingly collect Information from persons under 13 years of age. If you are under 13 years of age, you may review the Site only with involvement of a parent or guardian, and you may not use any portion of the Site that would require collection of personal information from you.

Linked Internet websites

The Site may provide hypertext links to other web sites that may contain privacy provisions that are different from those provided herein. We are not responsible for the collection, use or disclosure of information collected through those web sites, and we expressly disclaim any and all liability related to such collection, use or disclosure. You are encouraged to read the privacy policies of web sites reached through the use of links from the Site.

Modification

As we grow and new features are added, or legal requirements change, this privacy policy may be modified. Any changes to the Site’s privacy policy will be posted on the Site. All information submitted through the Site is subject to this privacy policy, as amended. This privacy policy was last updated in June of 2004.

How to contact us

If you have any questions or complaints about our Site, our Privacy Policy, or the Information we collect, please contact us at helix@helixbiopharma.com.

Jacek Antas

Chief Executive Officer

Jacek Antas is a shareholder of the Company, has spent more than 25 years in the financial services industry holding various positions in sales and consulting.

Mr. Antas obtained a master’s degree from the Warsaw School of Economics and has served as a board member of various
companies throughout his career.

This will close in 0 seconds

James B. Murphy

Chief Financial Officer

Mr. Murphy is a certified public accountant with over thirty years of experience in finance and operations management. He is currently a consultant with Danforth Advisors LLC (“Danforth”), a leading provider of outsourced strategic and operational specialists across functions in the life sciences industry. While at Danforth, Mr. Murphy has served over fifteen private and publicly held life sciences companies as CFO and CFO Advisor, helping them secure over USD 0.5 billion in financing and successfully execute pivotal asset transactions. Mr. Murphy functions as a consultant to Helix pursuant to a consulting agreement between the Company and Danforth.

This will close in 0 seconds

Thomas Mehrling

Medical Adviser

Thomas Mehrling (PhD in Pharmacology and MD) has over 20 years’ experience in multinational Pharma companies developing novel oncology compounds from preclinical research through to registration. Prior to entering the industry, he spent 13 years as an MD at the University Hospital in Frankfurt, working on preclinical and translational projects. He served as Director of European Oncology at Mundipharma International (2003–2013), building the company’s first European oncology business from the ground up out of Cambridge, UK, and completing the clinical development, registration and launch of two major products in Europe, DepoCyte® and Levact® (Ribomustin® and Treanda®). In 2013, he led the establishment of the Mundipharma Group’s start-up, Mundipharma EDO, developing anti-cancer therapeutics for solid tumours out of Basel, Switzerland.

This will close in 0 seconds

Kim Gaspar

Director Quality Assurance

Kim is the Director of Quality Assurance at Helix BioPharma Corp. An experienced quality assurance professional with expertise in Canadian, US, and EU regulations, she has been involved in all aspects of Phase I/II biopharmaceutical product development over the years, including regulatory submissions, QC laboratory compliance, tech transfer and third-party oversight of CMC activities, clinical QA, and bioanalytical data analysis. Kim joined Helix in 2000, transitioning into QA in 2003. She holds a B.Sc in Biochemistry and a Ph.D in Veterinary Physiological Sciences, both from the University of Saskatchewan.

This will close in 0 seconds

Brenda Lee

Director Clinical Operations

Brenda is the Clinical Operations Director at Helix Biopharma Corp. A clinical research operations professional with 25 years of experience managing clinical trials, ranging from early Phase I to late Phase IIIb/IV studies, she brings experience in clinical study protocol writing and development, trial start-up and vendor management, and a proven track record in planning and managing clinical trials to quality standards, timelines and budget. Brenda joined Helix Biopharma Corp. in 2018, working to advance the clinical program of L-DOS47. She holds B.Sc and M.Sc. degrees from the University of Toronto, specializing in Nutritional Sciences and Human Biology.

This will close in 0 seconds

Jerzy Leszczynski

Director

Jerzy Leszczynski is a shareholder of the Company, has spent more than 35 years developing businesses and has served in the capacity of board member of various real estate development companies. Mr. Leszczynski obtained his Master of Science in Chemistry from the Warsaw Institute of Technology.

This will close in 0 seconds

Janusz Grabski

Director, Chair of Audit Committee

Janusz (John) Grabski is a lawyer specialized in corporate and real estate law with over twenty years of experience.

This will close in 0 seconds

Malgorzata Laube

Director

Malgorzata Laube has over 19 years of experience in nuclear medicine. In her last role with Alberta Health Services, she was the Department Supervisor, Nuclear Medicine at Royal Alexandra Hospital. Ms. Laube obtained a MSc degree in Environmental Engineering from the Warsaw University of Technology and is based in Edmonton, Alberta, Canada.

This will close in 0 seconds

Jacek Antas

Chairman of the Board

Jacek Antas is a shareholder of the Company, has spent more than 25 years in the financial services industry holding various positions in sales and consulting.

Mr. Antas obtained a master’s degree from the Warsaw School of Economics and has served as a board member of various
companies throughout his career.

This will close in 0 seconds

Jonathan Davis

Advisor, ADC Discovery

Jonathan Davis received his Ph.D. from University of California, San Francisco, where he studied protein structure and function using NMR. After a post-doc at Harvard Medical School exploring RNA selection and structure in the labs of Jack Szostak and Gerhard Wagner, he went to work at EMD Serono, where his work involved improving antibody-based therapeutics, inventing a platform technology for generating heterodimeric Fcs as a basis for multifunctional molecules, and developing a novel scaffold based on an artificially-designed protein from David Baker’s lab. In 2008 he took a job at Bristol-Myers Squibb in Waltham/Cambridge MA, working on antibody discovery and platform development in a wide range of therapeutic areas, with a particular focus on multispecific therapeutics. He moved to Madison, WI in 2019 to take on the role of VP of Innovation and Strategy at Invenra, a biotech focused on bispecific antibodies, and where he is currently head of the Scientific Advisory Board. In early 2024 he left the corporate world to found Creative Antibodies, a consulting firm that helps guide companies to successful antibody discovery and development projects, from mAbs to multispecifics, ADCs, and other formats. Outside of science, Jonathan is a conservatory trained cellist, plays numerous other instruments, and founded the UCSF Orchestra (now Symphony Parnassus) in San Francisco, where he was Music Director for six years.

This will close in 0 seconds

Davide Guggi

Advisor, CMC

Davide graduated as a pharmacist and received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. He has over 20 years of experience in the pharmaceutical industry, principally in the field of oncology. At the beginning of his career, Davide led oncology business units and commercial departments at Mundipharma and Gilead across Austria and Eastern Europe. Since over 10 years he has been working as a CMC expert, covering operational and regulatory CMC functions on behalf of over 20 different small- and medium-sized biotech companies across the world. He has served as CMC Director and CSO/CTO for several years, developing both small molecules and biologics (mABs, Fab, ADCs and Radio-immuno-conjugates) from early discovery to NDA/BLA in the US, EU and Canada, with a focus on First-in-Human and Phase I/II studies in oncology indications.

This will close in 0 seconds

[sibwp_form id=1]

This will close in 0 seconds

Tumor Defense Breaker™, L-DOS47

L‑DOS47 is a first‑in‑class, clinical-stage antibody‑enzyme conjugate designed to deliver a game-changing assist to anti-cancer immunity and today’s leading cancer immunotherapies for the treatment of prevalent, hard-to-treat solid tumors. The compound precisely targets CEACAM6, a cell-surface protein overexpressed in non‑small cell lung cancer (NSCLC) and other aggressive tumors, where it delivers an enzymatic payload that raises the extracellular pH of the acidic tumor microenvironment (TME). By neutralizing tumor acidity, L-DOS47 restores immune cell infiltration and activity, helps turn immunologically “cold” tumors “hot”, and enhances the therapeutic reach of immune checkpoint inhibitors. With patented composition-of-matter coverage through 2036 and demonstrated synergy with PD-1 inhibitor, pembrolizumab, L-DOS47 is poised to significantly increase the efficacy of immune checkpoint blockade and unlock broader and more durable responses in NSCLC and other aggressive solid tumors.



Read more

This will close in 0 seconds

LEUMUNA™

LEUMUNA™ is an oral immune checkpoint modulator designed to activate the donor immune system to recognize and fight relapsing leukemia in patients who have undergone allogeneic stem cell transplantation (allo-SCT). Although a life-saving procedure, up to 30% of patients who undergo allo-SCT see their cancer return, facing a median survival of just four months. LEUMUNA aims to offer these patients a new lease on life, by activating an immune cascade and inciting graft-versus-leukemia (GvL) effect, potentially offering long-term remission. Backed by strong preclinical data and a promising safety record from trials with its precursor compound, ulodesine, LEUMUNA offers a patient‑friendly, oral approach to a difficult-to-treat condition, with patent protection through 2041 and an Orphan Drug Designation granted by the US FDA.



Read more

This will close in 0 seconds

GEMCEDA™

GEMCEDA is a first-in-class oral prodrug of gemcitabine that opens up the possibility for convenient at-home administration, metronomic dosing and seamless integration into combination regimens with immune checkpoint inhibitors. To date, gemcitabine is only administered intravenously because oral forms have shown poor bioavailability of about 10%. GEMCEDA was developed as a prodrug to enable new uses of gemcitabine by combining it with cedazuridine, an enzyme inhibitor that helps boost its bioavailability to 90%. This remarkable innovation allows for greater flexibility in dosing schedules, fewer clinic visits, and a better quality of life, while achieving bioavailability on par with intravenous gemcitabine. Supported by a well‑established safety profile, scalable manufacturing, and patent coverage to 2043, GEMCEDA reimagines how chemotherapy can fit into patients’ lives.



Read more

This will close in 0 seconds